ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

Tune in to the ASCO in Action podcast series for analysis and commentary on cancer policy and practice issues. The podcast is available through iTunes or Google Play.

March 17, 2022

Congress is considering several cancer policy priorities this week, including the PREVENT Pandemics Act, Cures 2.0, and legislation to authorize ARPA-H.

March 17, 2022

On March 17, the American Society of Clinical Oncology (ASCO) is hosting a meeting with key research stakeholders to discuss possible solutions and calls-to-action to optimize cancer clinical trials and facilitate routine patient access to trials closer to where they live.

March 15, 2022

The Association for Clinical Oncology (ASCO) is holding its annual Advocacy Summit Week of Action from April 4-8, during which ASCO members are encouraged to connect with their Members of Congress about policies and legislation that impact cancer care and research.

March 15, 2022

The National Academies of Sciences, Engineering, and Medicine (NASEM) issued a new report recommending the National Institutes of Health (NIH) implement new guidelines to standardize the collection of data on sex, gender, and sexual orientation. 

March 15, 2022

The American Society of Clinical Oncology (ASCO) is currently accepting applications for its project to improve rates of recommended vaccinations for adults with cancer. The project is part of a five-year cooperative agreement between the Centers for Disease Control and Prevention (CDC) and the Council of Medical Specialty Societies (CMSS). ASCO will select seven participants for the project in the Spring of 2022.

March 15, 2022

The U.S. Food and Drug Administration and the American Society of Clinical Oncology are holding a free virtual workshop, May 3 - 5, on dose optimization for anticancer drug treatment. This timely workshop will bring together thought leaders from academia, industry, regulatory agencies, and patient groups to discuss challenges and opportunities to improve dose selection for patients.

March 11, 2022

The Fiscal Year 2022 omnibus funding bill provides $45 billion for the National Institutes of Health (NIH), including $6.9 billion for the NCI. The Association for Clinical Oncology (ASCO) commends Congress for their enthusiastic, bipartisan support for continued investment in biomedical research.

March 11, 2022

On March 11, 2022, the Food and Drug Administration approved olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients must be selected for therapy based on an FDA-approved companion diagnostic for olaparib.

March 10, 2022

Members of the Regulatory Relief Coalition—including the Association for Clinical Oncology (ASCO)—participated in a week of action to call on Congress to pass the Improving Seniors’ Timely Access to Care Act (H.R. 3173/S. 3018). The bipartisan legislation would help protect patients from unnecessary care delays by streamlining and standardizing the prior authorization process under the Medicare Advantage program. More than 450 organizations currently endorse the bill.

March 9, 2022

The Centers for Medicare & Medicaid Services (CMS) announced that it will apply the Merit-based Incentive Payment System (MIPS) automatic extreme and uncontrollable circumstances (EUC) policy to all individual Merit-based Incentive Payment System (MIPS) eligible clinicians for the 2021 performance period.

March 8, 2022

The College of American Pathologists (CAP) and the American Society of Clinical Oncology (ASCO) hosted a virtual Immune Checkpoint Inhibition (ICI) Predictive Factor Summit to bring together stakeholders from the U.S. Food and Drug Administration (FDA), Centers for Medicare and Medicaid Services (CMS), National Institutes of Health (NIH), health insurance organizations, pharmaceutical companies, in vitro diagnostics manufacturers, and patient advocate organizations.

March 8, 2022

Marking International Women’s Day, ASCO and City Cancer Challenge Foundation (C/Can) are announcing their Leadership Programme for Women in Oncology, which seeks to address the specific challenges and barriers faced by women leaders in oncology and aims to strengthen leadership mindsets and skills of women working to improve access to equitable, quality cancer care in C/Can cities.

March 7, 2022

The Association for Clinical Oncology (ASCO) submitted comments in response to the Centers for Medicare & Medicaid Services’ (CMS) Contract Year 2023 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit Programs proposed rule. The rule proposes changes to advance the administration’s efforts to improve consumer protections, reduce disparities, and improve health equity in the MA and Part D programs.

March 7, 2022

On March 4, 2022, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting.

March 2, 2022

ASCO stands with our Ukrainian members, the worldwide oncology community, and healthcare providers around the globe in condemning Russia’s unprovoked war on Ukraine. We call for an immediate cessation of these hostilities and demand full protection and safety for all Ukrainian patients, healthcare workers, and medical facilities.

Pages